Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

INSM - Insmed - Deel 15

2.002 Posts
Pagina: «« 1 ... 37 38 39 40 41 ... 101 »» | Laatste | Omlaag ↓
  4. [verwijderd] 11 juli 2007 12:38

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Posted by: rod5247
    In reply to: None Date:7/10/2007 6:47:36 PM
    Post #of 5291

    !!!Still to be published - Allan/Goldfine - Breastcancer research success! (5 Ratings) 10-Jul-07 10:50 am 1: J Cell Biochem. 2007 Jun 11; [Epub ahead of print]Click here to read Links
    Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
    Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID.

    Diabetes and Endocrine Research, University of California, San Francisco/Mt. Zion Medical Center, San Francisco, California.

    We have reported that nordihydroguaiaretic acid (NDGA) inhibits the tyrosine kinase activities of the IGF-1 receptor (IGF-1R) and the HER2 receptor in breast cancer cells. Herein, we studied the effects of NDGA on the growth of estrogen receptor (ER) positive MCF-7 cells engineered to overexpress HER2 (MCF-7/HER2-18). These cells are an in vitro model of HER2-driven, ER positive, tamoxifen resistant breast cancer. NDGA was equally effective at inhibiting the growth of both parental MCF-7 and MCF-7/HER2-18 cells. Half maximal effects for both cell lines were in the 10-15 microM range. The growth inhibitory effects of NDGA were associated with an S phase arrest in the cell cycle and the induction of apoptosis. NDGA inhibited both IGF-1R and HER2 kinase activities in these breast cancer cells. In contrast, Gefitinib, an epidermal growth factor receptor inhibitor but not an IGF-1R inhibitor, was more effective in MCF-7/HER2-18 cells than in the parental MCF-7 cells and IGF binding protein-3 (IGFBP-3) was more effective against MCF-7 cells compared to MCF-7/HER2-18. MCF-7/HER2-18 cells are known to be resistant to the effects of the estrogen receptor inhibitor, tamoxifen. Interestingly, NDGA not only inhibited the growth of MCF-7/HER2-18 on its own, but it also demonstrated additive growth inhibitory effects when combined with tamoxifen. These studies suggest that NDGA may have therapeutic benefits in HER2-positive, tamoxifen resistant, breast cancers in humans. J. Cell. Biochem. (c) 2007 Wiley-Liss, Inc.

    PMID: 17562544 [PubMed - as supplied by publisher]

    www.ncbi.nlm.nih.gov/sites/entrez?Db=...

    You have rated

    iinfromu

    ,

    --------------------------------------------------------------------------------

    View Messages

    Ignore User

    Report Abuse

    < Previous Message | Next Message >


  6. [verwijderd] 11 juli 2007 12:56

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    marieke2 schreef:

    INSM-18 cancer study?
    tinyurl.com/29hxak

    From Q1 results SEC filing: ^^$0.5 million in initial license income from our agreement with NAPO Pharmaceuticals, Inc.
    die link gaat niet over napo
    en napo deal was al in jan/febr
    toen ook op ihub gepost en waarom geen pr erover..
    waarschijnlijk toen ivm de rechtzaak

    maar ins-18 verwacht ik op korte termijn niet veel van
  9. [verwijderd] 11 juli 2007 15:24

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Tercica,Genentech In Pact For Growth Hormone,IGF-1 Combo Devt
    Last update: 7/10/2007 4:22:08 PM
    DOW JONES NEWSWIRES Tercica Inc. (TRCA) signed an agreement with Genentech Inc. (DNA) worth up to $53 million for the development, manufacture and commercialization of two products. The Brisbane, Calif., biopharmaceutical company said it is eligible to receive up to $53 million in equity payments, opt-in payments, research and development cost reimbursement and milestone payments. Genentech will also buy 708,591 shares of Tercica stock for $4 million in connection with the transaction. The two products contain Genentech's recombinant human growth hormone Nutropin AQ and Tercica's recombinant insulin-like growth factor-1 Increlex. The products treat short stature, adult growth hormone deficiency and other metabolic disorders. Pending U.S. Food and Drug Administration guidance, Tercica plans to initiate Phase II clinical development in 2008 of one combination product for patients with low IGF-1 level and short stature not associated with growth hormone deficiency, and a second combination product for patients with adult growth hormone deficiency. Tercica shares were halted at 4:10 p.m. EDT at $5.42, down 21 cents, or 3.7%. -Jonathan Vuocolo; 201-938-5400; AskNewswires@dowjones.com (END) Dow Jones Newswires
  10. [verwijderd] 11 juli 2007 15:33

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0



    Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference
    RICHMOND, Va., Jul 09, 2007 (BUSINESS WIRE) -- Insmed Inc. (NASDAQ:INSM), a biopharmaceutical company focused on the development and approval of drugs for the treatment of metabolic diseases with unmet medical needs, today announced that it will present at this week's C.E. Unterberg, Towbin (CEUT) Emerging Growth Opportunities Conference in New York City.

    The conference, to be held at the Mandarin Oriental Hotel in New York City, will run from Tuesday, July 10th through Thursday, July 12th. Dr. Geoffrey Allan, Ph.D., Insmed's President and CEO, will make the presentation on Thursday, July 12th at 8:30 a.m.; the Company will also hold one-on-one meetings with investment firm representatives. A live video Webcast of the presentation will be available at the investor relations section of Insmed's website, www.insmed.com.

    Dr. Allan said, "We are especially pleased to be participating in this year's CEUT conference, because it gives us an ideal forum to present our dual strategy growth plan, based on our approved proprietary protein platform and the development and manufacture of follow-on biologics, to a crucial audience of investment managers and analysts. Insmed has a very timely story to tell, and we are glad to get this opportunity to tell it at such a high-visibility event

  12. ludwig mack 11 juli 2007 15:53

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    Laatste 0,81 15:48 100
    +/- 0,02 2,41%
    Open 0,78 15:30
    Slot 0,79 10/7
    Hoog 0,81 15:47
    Laag 0,78 15:30
    Volume 42.462

    geen daling dus ....
  13. [verwijderd] 11 juli 2007 15:57

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ludwig mack schreef:

    Laatste 0,81 15:48 100
    +/- 0,02 2,41%
    Open 0,78 15:30
    Slot 0,79 10/7
    Hoog 0,81 15:47
    Laag 0,78 15:30
    Volume 42.462

    geen daling dus ....

    waarom ook?
    "p
    niets met insm te maken
    eerder positief omdat insm ook in joint development committee zit
  14. ludwig mack 11 juli 2007 16:02

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    quote:

    marieke2 schreef:


    Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference
    RICHMOND, Va., Jul 09, 2007 (BUSINESS WIRE) -- Insmed Inc. (NASDAQ:INSM), a biopharmaceutical company focused on the development and approval of drugs for the treatment of metabolic diseases with unmet medical needs, today announced that it will present at this week's C.E. Unterberg, Towbin (CEUT) Emerging Growth Opportunities Conference in New York City.

    The conference, to be held at the Mandarin Oriental Hotel in New York City, will run from Tuesday, July 10th through Thursday, July 12th. Dr. Geoffrey Allan, Ph.D., Insmed's President and CEO, will make the presentation on Thursday, July 12th at 8:30 a.m.; the Company will also hold one-on-one meetings with investment firm representatives. A live video Webcast of the presentation will be available at the investor relations section of Insmed's website, www.insmed.com.

    Dr. Allan said, "We are especially pleased to be participating in this year's CEUT conference, because it gives us an ideal forum to present our dual strategy growth plan, based on our approved proprietary protein platform and the development and manufacture of follow-on biologics, to a crucial audience of investment managers and analysts. Insmed has a very timely story to tell, and we are glad to get this opportunity to tell it at such a high-visibility event


    Insmed has a very timely story to tell,

    ja, wat voor nieuws .........

    timely, volgens kramer's: tijdig, op de juiste tijd of op het geschikte ogenblik komend, van pas, actueel ........
    nou, nou, dat wordt wat ;-)
  15. ludwig mack 11 juli 2007 16:04

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    quote:

    crackedtooth schreef:

    [quote=ludwig mack]
    Laatste 0,81 15:48 100
    +/- 0,02 2,41%
    Open 0,78 15:30
    Slot 0,79 10/7
    Hoog 0,81 15:47
    Laag 0,78 15:30
    Volume 42.462

    geen daling dus ....

    [/quote]

    waarom ook?
    "p
    niets met insm te maken
    eerder positief omdat insm ook in joint development committee zit
    nee, maar als ze voor insm hadden gekozen, hadden zij royalties kunnen vangen, zo is het wel natuurlijk ......., nu doen ze het zelf samen, zonder insm toch!
    wat levert die committee ze op ?
  18. [verwijderd] 11 juli 2007 17:03

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ludwig mack schreef:

    [quote=marieke2]


    Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference
    RICHMOND, Va., Jul 09, 2007 (BUSINESS WIRE) -- Insmed Inc. (NASDAQ:INSM), a biopharmaceutical company focused on the development and approval of drugs for the treatment of metabolic diseases with unmet medical needs, today announced that it will present at this week's C.E. Unterberg, Towbin (CEUT) Emerging Growth Opportunities Conference in New York City.

    The conference, to be held at the Mandarin Oriental Hotel in New York City, will run from Tuesday, July 10th through Thursday, July 12th. Dr. Geoffrey Allan, Ph.D., Insmed's President and CEO, will make the presentation on Thursday, July 12th at 8:30 a.m.; the Company will also hold one-on-one meetings with investment firm representatives. A live video Webcast of the presentation will be available at the investor relations section of Insmed's website, www.insmed.com.

    Dr. Allan said, "We are especially pleased to be participating in this year's CEUT conference, because it gives us an ideal forum to present our dual strategy growth plan, based on our approved proprietary protein platform and the development and manufacture of follow-on biologics, to a crucial audience of investment managers and analysts. Insmed has a very timely story to tell, and we are glad to get this opportunity to tell it at such a high-visibility event


    [/quote]

    Insmed has a very timely story to tell,

    ja, wat voor nieuws .........

    timely, volgens kramer's: tijdig, op de juiste tijd of op het geschikte ogenblik komend, van pas, actueel ........
    nou, nou, dat wordt wat ;-)

    INSMED THERAPEUTIC PROTEINS...is wel redelijk actueel ,een partner ?
  19. [verwijderd] 11 juli 2007 17:37

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    vraag op ihub

    "
    Is Tercica basically trying to develop their own IPLEX? And if so, wouldn't they have gained valuable scientific knowledge and insight into how to do just that during the technical/scientific discussions and arguments presented at the patent litigation trial which they won?
    "

    antwoord (mijn eigen, commentaar welkom):

    www.investorshub.com/boards/read_msg....
  20. ludwig mack 11 juli 2007 18:01

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    quote:

    crackedtooth schreef:

    vraag op ihub

    "
    Is Tercica basically trying to develop their own IPLEX? And if so, wouldn't they have gained valuable scientific knowledge and insight into how to do just that during the technical/scientific discussions and arguments presented at the patent litigation trial which they won?
    "

    antwoord (mijn eigen, commentaar welkom):

    www.investorshub.com/boards/read_msg....
    nou, chapeau, een mooi verhaal;
    heb niet geweten, of vergeten, dat jij dat was (waarom niet zelfde fake speudo als hier?)
    ik begrijp opmerking over het nut van je committee nu beter.
    gr
  21. ludwig mack 11 juli 2007 18:02

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    wat verwachten jullie van morgen, reakties graag, pleaseeeeee .....

    ik weet het echt niet, echt geen idee, veel van het oude of veel nieuws.
2.002 Posts
Pagina: «« 1 ... 37 38 39 40 41 ... 101 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.003
AB InBev 2 5.488
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.323
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.555
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.660
Aedifica 3 902
Aegon 3.258 322.678
AFC Ajax 538 7.087
Affimed NV 2 6.288
ageas 5.844 109.887
Agfa-Gevaert 14 2.048
Ahold 3.538 74.313
Air France - KLM 1.025 35.008
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.377
Allfunds Group 4 1.469
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.819
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 242.828
AMG 971 133.150
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 485
Antonov 22.632 153.605
Aperam 92 14.961
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.733
Arcelor Mittal 2.033 320.625
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.725
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.087
ASML 1.766 106.219
ASR Nederland 21 4.452
ATAI Life Sciences 1 7
Atenor Group 1 484
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.639
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392